CBIZ Discloses Material Weaknesses, Non-Reliance on Internal Controls, and Restatement Amid $5B Acquisition
CBZ sits 92% above its 52-week low of $24.29.
Summary
CBIZ disclosed material weaknesses in internal controls, withdrew reliance on prior control reports, and restated Q1 2026 earnings downward by $8.8 million — all on the same day a $5 billion acquisition was announced.
Key Events · Legal and Risk Events · CBZ
-
Material Weaknesses Identified
Two material weaknesses found: one in ESPP administration (excess share purchases of 481,049 shares over 2.5 years) and one in goodwill reassignment after organizational changes. Management concluded internal control over financial reporting was not effective as of Dec 31, 2025.
-
Non-Reliance on Prior Control Reports
Audit Committee determined that management's conclusions on internal controls and KPMG's audit opinion on ICFR as of Dec 31, 2025 should no longer be relied upon. The company will file an amended 10-K with an adverse opinion on controls.
-
Financial Restatement
Q1 2026 net income revised down by $8.8 million (from $161.6M to $152.8M), EPS reduced by $0.14 (from $2.63 to $2.49), due to immaterial corrections from the ESPP excess purchases.
-
Voluntary Rescission Offer
Company will offer to repurchase affected shares from ESPP participants at the discounted purchase price plus interest, or compensate for losses on sold shares. Maximum potential payout estimated at $20.2 million as of June 30, 2026.
Analysis · CBZ · Trade & Services
CBIZ disclosed two material weaknesses in internal control over financial reporting — one related to excess share purchases under its employee stock plan, the other to goodwill reassignment — and said its prior internal control reports can no longer be relied upon. The company will restate Q1 2026 results, reducing net income by $8.8 million and EPS by $0.14. It also launched a voluntary rescission offer that could cost up to $20.2 million. This comes on the same day Grant Thornton Advisors announced a $5 billion all-cash acquisition of CBIZ at $55 per share, a deal that may be complicated by the control failures and restatement.
At the time of this filing, CBZ was trading at $46.70 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $24.29 to $77.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.